Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
August 4th, 2022
4.9K views
This protocol describes the consecutive implantation of an osmotic pump to induce abdominal aortic aneurysm by angiotensin II release in apolipoprotein E (ApoE) deficient mice and of a vascular access port with a jugular vein catheter for repeated drug treatment. Monitoring of aneurysm development by 3D ultrasound is effectively conducted despite dorsal implants.
Overview
This protocol outlines the implantation of an osmotic pump and a vascular access port in ApoE deficient mice to study abdominal aortic aneurysm progression. It emphasizes the use of 3D ultrasound for monitoring aneurysm development.
Key Study Components
Area of Science
- Neuroscience
- Cardiovascular research
- Drug testing protocols
Background
- Abdominal aortic aneurysms (AAAs) are significant health concerns.
- ApoE deficient mice serve as a model for studying AAAs.
- Angiotensin II is used to induce aneurysm formation.
- Monitoring techniques are crucial for assessing aneurysm progression.
Purpose of Study
- To establish a reliable method for inducing and monitoring AAAs in mice.
- To facilitate drug testing aimed at reducing aneurysm progression.
- To improve the understanding of aneurysm development in a controlled environment.
Methods Used
- Implantation of an osmotic pump for angiotensin II release.
- Insertion of a vascular access port with a jugular vein catheter.
- 3D ultrasound imaging for monitoring aortic changes.
- Detailed surgical procedures for catheterization and pump implantation.
Main Results
- Successful implantation of devices in mice.
- Effective monitoring of aneurysm development using 3D ultrasound.
- Establishment of a workflow for drug testing in AAA models.
- Demonstration of the feasibility of repeated drug administration.
Conclusions
- The protocol provides a comprehensive approach to studying AAAs.
- 3D ultrasound is a valuable tool for monitoring aneurysm progression.
- This method can enhance drug testing for AAA therapies.
Frequently Asked Questions
What is the significance of using ApoE deficient mice?
ApoE deficient mice are a relevant model for studying abdominal aortic aneurysms as they mimic aspects of human disease.
How does the osmotic pump function in this study?
The osmotic pump releases angiotensin II to induce the formation of abdominal aortic aneurysms in the mice.
What imaging technique is used to monitor aneurysm development?
3D ultrasound imaging is utilized to effectively monitor changes in aortic diameter and morphology.
Can the vascular access port be used for other treatments?
Yes, the vascular access port allows for repeated intravenous drug administration, making it versatile for various treatments.
What are the main outcomes of this protocol?
The protocol successfully establishes a method for inducing AAAs and monitoring them, facilitating drug testing.
Is this method applicable to other mouse models?
While designed for ApoE deficient mice, adaptations may allow use in other models with similar aneurysm characteristics.
Executive Industry Relevance
Reliable preclinical models are essential for evaluating therapeutic strategies targeting abdominal aortic aneurysm (AAA) progression, a disease with limited pharmaceutical options. This protocol integrates sustained drug delivery and high-resolution 3D ultrasound monitoring in a mouse model, enabling robust assessment of candidate interventions. The approach supports translational continuity and predictive confidence at the discovery-to-preclinical inflection point for vascular disease portfolios.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses targeting AAA progression in a disease-relevant in vivo system.
- Supports biological de-risking by allowing longitudinal assessment of drug effects on aneurysm morphology and growth.
- Facilitates functional target validation through quantitative monitoring of aortic diameter and volume changes.
Screening & Assay Development
- Prepares validated animal models for downstream efficacy screening of novel compounds.
- Standardizes drug administration via central venous catheterization, ensuring reproducibility across cohorts.
- Generates quantitative 3D ultrasound outputs for objective comparison of treatment effects.
Translational & Preclinical Research
- Aligns preclinical endpoints with clinical imaging modalities by employing 3D ultrasound for disease monitoring.
- Enables risk-adjusted advancement decisions based on real-time, non-invasive assessment of disease progression.
- Supports biomarker development by correlating imaging data with histological and blood-based analyses.
Pipeline & Workflow Integration
This protocol bridges early discovery and preclinical validation by enabling sustained drug testing and quantitative disease monitoring in a single workflow.
- Discovery Biology: Provides a platform for hypothesis testing and mechanistic de-risking in AAA research.
- Screening: Delivers reproducible, quantitative imaging outputs for compound evaluation.
- Analytics: Supports statistical comparison of treatment groups using serial 3D ultrasound measurements.
- Translational Research: Facilitates continuity from animal model findings to clinical imaging endpoints.
- Enterprise Reuse: Offers a reusable infrastructure for testing diverse drug candidates and regimens in vascular disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in AAA drug development.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical efficacy studies.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by enabling robust, quantitative readouts.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of vascular disease assets.
Implementation Considerations
- Requires expertise in microsurgical catheterization and animal model management.
- Demands access to high-resolution 3D ultrasound imaging and analytical software.
- Necessitates rigorous cross-team standardization of surgical and imaging procedures.
- Adaptation may be needed for use in alternative mouse models or disease contexts.
- Catheter patency and device integrity are critical for reliable drug delivery and data quality.
Biopharma FAQs
Why is null hypothesis testing critical for AAA drug validation?
Null hypothesis testing enables objective evaluation of whether candidate drugs significantly alter aneurysm progression, supporting robust target validation in the mouse AAA model using quantitative 3D ultrasound outputs.
How does independent variable isolation occur in serial drug administration?
Central venous catheterization allows precise control of drug dosing and timing, isolating the treatment variable and minimizing confounding factors during AAA progression studies.
What do quantitative 3D ultrasound measurements enable in AAA studies?
Serial 3D ultrasound provides reproducible measurements of aortic diameter, volume, and morphology, enabling statistical comparison of treatment effects and supporting data-driven advancement decisions.
Why are replication requirements important for cross-functional AAA research?
Replication ensures that observed drug effects on aneurysm progression are consistent and reproducible, facilitating collaboration between discovery, preclinical, and translational teams.
What statistical analysis capabilities are needed before AAA protocol implementation?
Teams must be equipped to analyze longitudinal imaging data, compare treatment groups, and assess significance of observed changes in aneurysm metrics to inform portfolio decisions.
